4. Bibliografia
4. Bibliografia:
1.
Clemons M, Goss P. 2001. Estrogen and the risk of breast cancer. N Engl J Med 344: 276-85
2.
Safe SH. 1998. Interactions between hormones and chemicals in breast cancer. Annu Rev Pharmacol Toxicol 38: 121-58
3.
Kuukasjarvi T, Kononen J, Helin H, Holli K, Isola J. 1996. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 14: 2584-9
4.
Howell A, DeFriend DJ, Robertson JF, Blamey RW, Anderson L, et al. 1996. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 74: 300-8
5.
Osborne CK. 1998. Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609-18
6.
Sheen YY, Simpson DM, Katzenellenbogen BS. 1985. An evaluation of the role of antiestrogen-binding sites in mediating the growth modulatory effects of antiestrogens: studies using t-butylphenoxyethyl diethylamine, a compound lacking affinity for the estrogen receptor. Endocrinology 117: 561-4
7.
Mesange F, Sebbar M, Kedjouar B, Capdevielle J, Guillemot JC, et a l. 1998. Microsomal epoxide hydrolase of rat liver is a subunit of theanti-oestrogen-binding site. Biochem J 334 ( Pt 1): 107-12
8.
Duval D, Durant S, Homo-Delarche F. 1983. Non-genomic effects of steroids. Interactions of steroid molecules with membrane structures and functions. Biochim Biophys Acta 737: 409-42
9.
Clarke R, Leonessa F, Welch JN, Skaar TC. 2001. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53: 25-71
10.
Lindner DJ, Borden EC. 1997. Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis. Int J Cancer 71: 456-61
11.
Lien EA, Lonning PE. 2000. Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy. Cancer Treat Rev 26: 205-27
12.
Saville B, Wormke M, Wang F, Nguyen T, Enmark E, et al. 2000. Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 275: 5379-87
13.
Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, et al. 1997. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277: 1508-10
14.
Altucci L, Addeo R, Cicatielo L, Dauvois S, Parker MG, et al. 1996. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activationand p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 12: 2315-24
15.
Montano MM, Katzenellenbogen BS. 1997. The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens. Proc Natl Acad Sci U S A 94: 2581-6
16.
Smith CL, Nawaz Z, O'Malley BW. 1997. Coactivator and corepressor regulation of the agonist/antagonist activity of the m ix ed antiestrogen, 4-hydroxytamox ifen. M ol Endocrinol 11: 657-66
17.
Ali S, Coombes RC. 2002. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2: 101-12
18.
Kato S. 2001. Estrogen receptor-mediated cross-talk with growth factor signaling pathways. Breast Cancer 8: 3-9
19.
Joel PB, Traish AM, Lannigan DA. 1998. Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. J Biol Chem 273: 13317-23
20.
Chen D, Riedl T, Washbrook E, Pace PE, Coombes RC, et al. 2000. Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with T FIIH and participation of CDK7. Mol Cell 6: 127-37
21.
Joel PB, Smith J, Sturgill T W, Fisher T L, Blenis J, Lannigan DA. 1998. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol 18: 1978-84
22.
Sivaraman VS, Wang H, Nuovo GJ, Malbon CC. 1997. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99: 1478-83
23.
Gee JM, Robertson JF, Ellis IO, Nicholson RI. 2001. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95: 247-54
24.
Datta SR, Brunet A, Greenberg ME. 1999. Cellular survival: a play in three Akts. Genes Dev 13: 2905-27
25.
Martin MB, Franke TF, Stoica GE, Chambon P, Katzenellenbogen BS, et al. 2000. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 141: 4503-11
26.
Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. 2001. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276: 9817-24
27.
Testa JR, Bellacosa A. 2001. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A 98: 10983-5
28.
Guvakova MA, Surmacz E. 1997. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res 57: 2606-10
29.
Rochefort H. 1994. Oestrogens, proteases and breast cancer. From cell lines to clinical applications. Eur J Cancer 30A: 1583-6
30.
Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, et al. 1999. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor s ubstrate-1 expression in vitro and in vivo. Mol Endocrinol 13: 787-96
31.
Ruan W, Catanese V, Wieczorek R, Feldman M, Kleinberg DL. 1995. Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. Endocrinology 136: 1296-302
32.
Stewart AJ, Johnson MD, May FE, Westley BR. 1990. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cels. J Biol Chem 265: 21172-8
33.
Nicholson RI, Gee JM. 2000. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer 82: 501-13
34.
Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. 2001. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: 1852-7
35.
Morel Y, Barouki R. 1999. Repression of gene expression by oxidative stress. Biochem J 342 Pt 3: 481-96
© 2010 BioCancer.com